Longboard pharmaceuticals initiates phase 3 deep sea study evaluating bexicaserin in dravet syndrome

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global phase 3 deep sea study evaluating its investigational drug bexicaserin for the treatment of seizures associated with dravet syndrome in participants two years of age and older. “we are thrilled to announce the initiation of our global phase 3.
LBPH Ratings Summary
LBPH Quant Ranking